ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
27 Jan 2021 21:33

JOINN Laboratories IPO Initiation: On-Demand Science

JOINN is seeking a listing hearing for a H-Share listing to raise up to $600 million, according to press reports. On balance, we think that JOINN’s...

Logo
304 Views
Share
24 Jan 2021 05:49

China Equity Strategy: Domestic Funds Rush to Deploy Capital in Hong Kong Market

China mainland funds have accelerated their capital deployment in Hong Kong market in the new year. The fund inflow to Hong Kong has exceeded RMB...

Logo
Roger Xie
401 Views
Share
bullishWuxi Biologics
20 Jan 2021 10:01

Wuxi Biologics (2269 HK) - A Monopoly in China Macromolecule CDMO

This article analyzed WuXi Biologics in terms of market potential and position, technology platforms & R&D capability, business analysis, and...

Logo
294 Views
Share
bullishYidu Tech Inc
10 Jan 2021 13:45

ECM Weekly (10 January 2021) - RLX Technology, Roiserv, Yidu Tech, and Placements

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
05 Jan 2021 10:53

Aequitas 2020 IPOs and Placements Performance - IPOs in the Limelight but Placements Stole the Show

2020 marked our second year of operations as an Independent Research Company, and our fifth year covering ECM. In 2020 we had an accuracy rate of...

Logo
405 Views
Share
x